Blocking P2X7 receptor curbs inflammation in human brain tissue
Researchers found that the P2X7 receptor drives inflammatory signaling in live human brain cell cultures and surgical tissue slices. Using an antagonist to block the receptor significantly reduced cytokine release and inflammation. The discovery points to a possible drug-repurposing strategy for conditions such as Alzheimer's, Parkinson's, traumatic brain injury, depression, and psychosis.
The study centered on the P2X7 receptor, which helps initiate inflammatory signaling in the brain. Researchers examined live human brain cell cultures and tissue slices obtained during neurosurgery. Blocking P2X7 with a specific antagonist sharply lowered cytokine release, suggesting this pathway is a potential target for reducing neuroinflammation.
Much of the work involved microglia, the brain's immune cells. To study them, scientists turned human peripheral monocytes from blood into microglia-like cells, mimicking a transformation seen during normal aging. This approach may offer a scalable way to investigate human microglial biology and test treatments. Published in Brain, the project was led by Professor Nicholas Barnes at the University of Birmingham.
If P2X7-blocking treatments prove safe and effective in people, they could eventually benefit patients with Alzheimer's, Parkinson's, traumatic brain injury, depression, psychosis, schizophrenia, or multiple sclerosis, along with caregivers and health systems. Because some existing medicines may already target this receptor, researchers could explore repurposing them, potentially shortening development paths. Still, clinical benefit remains uncertain until human trials confirm whether reducing this inflammatory signal changes symptoms or disease progression.